Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy

Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.28) per share which beat the analys

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to th

[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-st

Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial Of Coya 302 Targeting Regulatory T

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-st

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage bi

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

Top Wall Street analysts changed outlook for top names. See all changes on analyst ratings page. ONT

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA)

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

On May 12, 2026, Coya Therapeutics, Inc. (the "Company") entered into a Sales Agreement (the

Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.32) per share which beat the analys

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage bi

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

Shares of Coya Therapeutics, Inc. (NASDAQ: COYA - Get Free Report) have been assigned a consensus ra

The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integr

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Coya Therapeutics (NASDAQ:COYA) wit

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.34) per share which missed the anal

Coya Therapeutics, Inc.2,522,727 Shares of Common StockThis prospectus relates to the resale of up t

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

Coya Therapeutics (NASDAQ: COYA - Get Free Report) is projected to announce its Q4 2025 results befo

Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimi

Speakers on a Coya Therapeutics (NASDAQ: COYA) webinar outlined the company's scientific rationale a

D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and m

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Coya Therapeutics (NASDAQ:COYA) wit

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage b

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinic

D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and m

Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies t

  During Monday's session, 201 stocks hit new 52-week lows.

  During the Friday's sesion, 157 stocks hit new 52-week lows.